ArticleNPJ precision oncology2026
Prognostic impact of somatic mutations among patients with pleural and peritoneal mesothelioma.
Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesothelioma is a rare cancer with poor prognosis. Somatic mutations show prognostic value in smaller studies; however, detailed survival analysis of mutations, specific variants, and co-mutations are unknown. This study gathered one of the largest mesothelioma cohorts in North America to determine prognostic impact of treatments, tumor characteristics, and somatic mutations. Among 195 patients, 70% (n = 137) had pleural and 30% (n = 58) had peritoneal mesothelioma. NF2, TERT, and CDKN2A had worse OS in pleural mesothelioma. NF2 mutations with truncated NF2 protein (non-sense and frameshift with premature stop codon) had worse OS in pleural mesothelioma (log-rank-p < 0.001). Conversely, NF2 pathogenic mutations with loss-of-function/structural variants were not associated with OS, revealing that NF2 truncating mutations may drive NF2's prognostic impact. This is emphasized by higher mortality at 1-year (44% vs 7.7%, p = 0.044) and 18-months (69% vs 17%, p = 0.006) compared to non-truncating NF2 mutations. Overall, this study found that pleural and peritoneal mesothelioma have unique mutations with prognostic significance. Furthermore, as trials demonstrate varied results in NF2-targeted treatments, this study supports biomarker-informed strategies to guide trial enrollment and development of targeted-therapies.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.